First patient enrolled in a Phase 2 Study in T2DM patients with Olatec's NLRP3 inhibitor dapansutrile
The first patient with T2DM and diabetes-related complications has been enrolled in the clinical trial, DAPAN-DIA, in Basel, Switzerland,...
top of page
Browse by category
Search
Browse by tag
bottom of page